The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Targeted therapy using nanotechnology: focus on cancer
Open accessAbstract
Recent advances in nanotechnology and biotechnology have contributed to the development of engineered nanoscale materials as innovative prototypes to be used for biomedical applications and optimized therapy. Due to their unique features, including a large surface area, structural properties, and a long circulation time in blood compared with small molecules, a plethora of nanomaterials has been developed, with the potential to revolutionize the diagnosis and treatment of several diseases, in particular by improving the sensitivity and recognition ability of imaging contrast agents and by selectively directing bioactive agents to biological targets. Focusing on cancer, promising nanoprototypes have been designed to overcome the lack of specificity of conventional chemotherapeutic agents, as well as for early detection of precancerous and malignant lesions. However, several obstacles, including difficulty in achieving the optimal combination of physicochemical parameters for tumor targeting, evading particle clearance mechanisms, and controlling drug release, prevent the translation of nanomedicines into therapy. In spite of this, recent efforts have been focused on developing functionalized nanoparticles for delivery of therapeutic agents to specific molecular targets overexpressed on different cancer cells. In particular, the combination of targeted and controlled-release polymer nanotechnologies has resulted in a new programmable nanotherapeutic formulation of docetaxel, namely BIND-014, which recently entered Phase II clinical testing for patients with solid tumors. BIND-014 has been developed to overcome the limitations facing delivery of nanoparticles to many neoplasms, and represents a validated example of targeted nanosystems with the optimal biophysicochemical properties needed for successful tumor eradication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816 · cited 1×
“55–58 The way forward for the clinical translation of controlled-release polymeric nanoparticles was paved by the seminal work of Langer and Folkman in 1976, which demonstrated the controlled release of macromolecules from biodegradable polymers in a temporal manner.”
Cited by
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022) · Molecules · doi:10.3390/molecules27175730 · Cited by 904
SERS Nanoparticles in Medicine: From Label-Free Detection to Spectroscopic Tagging
Lane, L. A., Qian, X., & Nie, S. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00265 · Cited by 873
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Martins, P., Jesus, J., Santos, S., Raposo, L., Roma-Rodrigues, C., Baptista, P., & Fernandes, A. (2015) · Molecules · doi:10.3390/molecules200916852 · Cited by 716
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Srinivasarao, M., Galliford, C. V., & Low, P. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4519 · Cited by 671
Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances
Revia, R. A., & Zhang, M. (2016) · Materials Today · doi:10.1016/j.mattod.2015.08.022 · Cited by 612
Chitosan oligosaccharide: Biological activities and potential therapeutic applications
Muanprasat, C., & Chatsudthipong, V. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.013 · Cited by 520
Polymeric nanoparticles for targeted treatment in oncology: current insights
Joshi, M. D., Patravale, V., & Prabhu, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s56932 · Cited by 438
Stealth Coating of Nanoparticles in Drug-Delivery Systems
Fam, S. Y., Chee, C. F., Yong, C. Y., Ho, K. L., Mariatulqabtiah, A. R., & Tan, W. S. (2020) · Nanomaterials · doi:10.3390/nano10040787 · Cited by 422
Nanotechnology for Cancer Therapy Based on Chemotherapy
Zhao, C.-Y., Cheng, R., Yang, Z., & Tian, Z.-M. (2018) · Molecules · doi:10.3390/molecules23040826 · Cited by 330
Biomedical Applications of Recombinant Silk‐Based Materials
Aigner, T. B., DeSimone, E., & Scheibel, T. (2018) · Advanced Materials · doi:10.1002/adma.201704636 · Cited by 318
Nanoparticles in Clinical Translation for Cancer Therapy
Mundekkad, D., & Cho, W. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 305
Nanomedicine applied to translational oncology: A future perspective on cancer treatment
Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., & Prina-Mello, A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.08.006 · Cited by 296
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Jain, V., Kumar, H., Anod, H. V., Chand, P., Gupta, N. V., Dey, S., & Kesharwani, S. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.003 · Cited by 290
Pearce, A. K., & O’Reilly, R. K. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00456 · Cited by 275
Application of Nanotechnology in Drug Delivery
(2014) · InTech eBooks · doi:10.5772/57028 · Cited by 266
Synergistic nanomedicine by combined gene and photothermal therapy
Kim, J., Kim, J., Jeong, C., & Kim, W. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.018 · Cited by 262
Polymer-Based Nanomaterials for Drug-Delivery Carriers
Yadav, H. K. S., Almokdad, A. A., shaluf, S. I. M., & Debe, M. S. (2019) · Nanocarriers for Drug Delivery · doi:10.1016/b978-0-12-814033-8.00017-5 · Cited by 148
AbouAitah, K., Swiderska-Sroda, A., Farghali, A. A., Wojnarowicz, J., Stefanek, A., Gierlotka, S., Opalinska, A., Allayeh, A. K., Ciach, T., & Lojkowski, W. (2018) · Oncotarget · doi:10.18632/oncotarget.25470 · Cited by 83
Nanocarrier-based targeted pulmonary delivery: novel approaches for effective lung cancer treatment
Shah, M. R., Imran, M., & Ullah, S. (2019) · Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy · doi:10.1016/b978-0-12-816773-1.00006-7 · Cited by 5
Metadata
- Authors
- Sechi, M., Sanna, V., & Pala, N.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2014-01
- Volume
- 9
- Pages
- 467
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W1981412372
- Cited by
- 493
- References
- 130
- FWCI
- 19.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.